Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 100 shares, a decline of 99.5% from the February 29th total of 20,800 shares. Based on an average daily trading volume, of 2,200 shares, the days-to-cover ratio is presently 0.0 days.

Santen Pharmaceutical Price Performance

OTCMKTS:SNPHY remained flat at $9.75 during mid-day trading on Thursday. 288 shares of the company traded hands, compared to its average volume of 5,016. Santen Pharmaceutical has a 52-week low of $7.71 and a 52-week high of $10.80. The firm’s fifty day simple moving average is $9.95 and its 200-day simple moving average is $9.53.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.